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Berberine improved experimental 
chronic colitis by regulating 
interferon-γ- and IL-17A-producing 
lamina propria CD4+ t cells through 
AMPK activation
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Yasuyuki Shimomura1, Hiroshi Matsushita1, tien thi thuy nguyen2,3, Kazuko Koike1, 
Airi ikeda1, Shiho takashima1, Yasushi Yamasaki1, toshihiro inokuchi1, Hideaki Kinugasa1, 
Yusaku Sugihara1, Keita Harada1, Shingo eikawa4, Hidetoshi Morita2, Heiichiro Udono4 & 
Hiroyuki okada1
The herbal medicine berberine (BBR) has been recently shown to be an AMP-activated protein kinase 
(AMPK) productive activator with various properties that induce anti-inflammatory responses. We 
investigated the effects of BBR on the mechanisms of mucosal CD4+t cell activation in vitro and on 
the inflammatory responses in T cell transfer mouse models of inflammatory bowel disease (IBD). We 
examined the favorable effects of BBR in vitro, using lamina propria (LP) CD4+ t cells in t cell transfer 
IBD models in which SCID mice had been injected with CD4+CD45RBhigh T cells. BBR suppressed the 
frequency of ifn-γ- and Il-17A-producing LP CD4+ T cells. This effect was found to be regulated by 
AMPK activation possibly induced by oxidative phosphorylation inhibition. We then examined the 
effects of BBR on the same IBD models in vivo. BBR-fed mice showed AMPK activation in the LPCD4+ 
T cells and an improvement of colitis. Our study newly showed that the BBR-induced AMPK activation 
of mucosal CD4+ T cells resulted in an improvement of IBD and underscored the importance of AMPK 
activity in colonic inflammation.
Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal tract, occur-
ring primarily in young individuals.
Accumulating evidence suggests that IBD is caused by an inappropriate response of the innate and acquired 
immune systems to the commensal microbiota1. Among these immune systems, inflammatory CD4+ T cells in 
the colonic lamina propria (LP) are acknowledged as critical factors in the pathogenesis of IBD2.
Berberine (BBR) is a traditional Chinese herbal medicine extracted from Phellodendron bark and Coptis 
japonica and is used to treat gastrointestinal disorders, such as diarrhea, with few adverse events. BBR also exerts 
various types of effects, such as anti-tumor, anti-diabetic and anti-inflammatory effects3–8. BBR is known to 
activate AMPK, which is an enzyme that plays a role in cellular energy homeostasis and different fundamental 
cellular processes, including the cell proliferation, survival and metabolism. The beneficial effect of BBR has 
recently been considered to be due to the activation of AMPK9,10. The energy metabolism changes in immune 
cells have been accepted to be involved in immune regulation. Furthermore, AMPK signaling has been shown to 
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inhibit the inflammatory responses11–16. Therefore, BBR may be of potential therapeutic utility in the treatment 
of immune-mediated diseases.
Several reports have already shown the utility of BBR in the treatment of IBD17–20. Various mechanisms, such 
as repair of the epithelial barrier function and the regulation of innate and adoptive immune responses, have been 
indicated in these reports. However, detailed analyses, including the mechanisms of the AMPK activity against 
CD4+ T cells, especially LP CD4+ T cells, which are considered to be involved in the pathogenesis of IBD2, have 
not been performed. In addition, the widely used models of colitis are chemically induced, which is not appropri-
ate for representing the chronic inflammatory features of IBD.
In this report, we investigated the effect and inhibitory mechanisms of BBR on LP CD4+ T cells of IBD—in 
terms of the cellular energy metabolism related to AMPK activity—using a T cell transfer colitis model involv-
ing the transfer of naïve (CD4+CD45RBhigh) T cells into congenic immunodeficiency mice to induce CD4+ T 
cell-specific colitis. Our results provide new insight into how BBR regulates the LP CD4+ T cell function as well 
as underscore the importance of AMPK activity in colonic inflammation. In the future, given these results, the 
involvement of AMPK activity in colonic inflammation may lead to the development of new therapeutic targets 
that are safe and useful for treating IBD.
Results
BBR suppressed inflammatory cytokines of LP CD4+ t cells from colitis SciD mice in vitro. We 
first assessed the inhibitory effect of BBR on LP CD4+ T cell activation in vitro. LP CD4+ T cells of colitis SCID 
mice (colitis LP CD4+ T cells) injected with CD4+ CD45RBhigh T cells were isolated and stimulated with PMA 
plus ionomycin mixed with BBR or not. In this colitis model, a large amount of the Th1-related cytokine IFN-γ 
and a small amount of the Th17-related cytokine IL-17A are known to be secreted by LP CD4+ T cells21,22. 
Therefore, we analyzed the production of IFN-γ and IL-17A. BBR exerted a dose-dependent inhibitory effect 
but showed no cytotoxic effect at concentrations of 100 µM (Fig. 1A, Supplementary Fig. S1). Therefore, we per-
formed subsequent experiments with BBR 100 µM.
As shown in Fig. 1B,C, the frequency of IFN-γ-producing CD4+ T cells in BBR-treated colitis LP CD4+ T cells 
was significantly lower than in non-BBR-treated colitis LP CD4+ T cells. The frequency of IL-17A-producing 
CD4+ T cells was also lower in BBR-treated cells than in untreated cells. These results indicated that BBR directly 
affected the colitis LP CD4+ T cells, thereby reducing the Th1/Th17 responses.
BBR suppressed the Th1/Th17-related JAK/STAT pathway of LP CD4+ t cells collected from 
colitis SCID mice. We further investigated the expression of signal molecules correlated with Th1/Th17 acti-
vation. The JAK/STAT pathway is a major signal that regulates Th cell differentiation and their function23,24. The 
Th1-related signal transduction molecules JAK1, JAK2, and STAT1 were all suppressed by BBR addition. The 
Th17-related molecule STAT3 was also suppressed by BBR addition (Fig. 2A–D). These results further confirmed 
the direct effect of BBR on the immune responses in colitis LP CD4+ T cells.
BBR increased the AMPK activity and regulated the IFN-γ and IL-17A secretion from colitis LP 
CD4+ T cells. Given that recent reports indicated that AMPK plays a key role in T cell activation and that 
BBR increased AMPK activity, we hypothesized AMPK activity as a vital mechanism on BBR effects. Earlier 
studies had established that phosphorylation of AMPK at Thr172 correlates with AMPK activity25. We there-
fore first compared the AMPK expression by Western blotting between BBR-treated colitis LP CD4+ T cells and 
non-BBR-treated colitis LP CD4+ T cells. As expected, the phosphorylation state of AMPK at Thr172 (p-AMPK) 
expressions was significantly increased in BBR-treated colitis LP CD4+ T cells (Fig. 3A).
Next, we examined the relationship between the AMPK activity and inflammatory cytokines. We measured 
IFN-γ- and IL-17A-producing colitis LP CD4+ T cells using AMPK agonist, 5-Aminoimidazole-4-carboxamide 
ribonucleotide (AICAR) and antagonist, Compound C (C.C.). The addition of AICAR resulted in the suppres-
sion of the frequency of IFN-γ- and IL17A-producing colitis LP CD4+ T cells. In contrast to the effect of AICAR 
on colitis LP CD4+ T cells, the addition of C.C. increased the frequency of IFN-γ-producing colitis LP CD4+ T 
cells as well as that of IL-17A-producing LP CD4+ T cells (Fig. 3B,C). Furthermore, the addition of mixing with 
AICAR and C.C. increased the frequency of IFN-γ- and IL-17A-producing colitis LP CD4+ T cells in comparison 
to the addition of AICAR alone and decreased the frequency of IFN-γ- and IL-17A-producing colitis LP CD4+ T 
cells in comparison to the addition of C.C. alone (Fig. 3B,C).
Western blotting analysis showed that the p-AMPK activity of colitis LP CD4+ T cells was significantly 
increased by AICAR treatment and significantly suppressed by C.C. treatment (Fig. 3D,E). Furthermore, the 
p-AMPK activity of colitis LP CD4+ T cells was significantly suppressed by combination AICAR and C.C. treat-
ment in comparison to AICAR and increased in comparison to C.C. (Fig. 3D,E).
These data strongly indicated that the production of IFN-γ and IL-17A by colitis LP CD4+ T cells was regu-
lated through AMPK activities.
BBR affected the oxidative phosphorylation and decreased the total adenosine triphosphate 
production. AMPK is activated in response to stresses that deplete cellular adenosine triphosphate (ATP), 
such as low glucose, hypoxia, ischemia and heat shock26–28. Therefore, we compared the ATP production in 
BBR-treated colitis LP CD4+ T cells to that of non-BBR-treated colitis LP CD4+ T cells. As expected, the ATP 
production of BBR-treated colitis LP CD4+ T cells was significantly decreased relative to that of non-BBR-treated 
colitis LP CD4+ T cells (Fig. 4A).
ATP is produced mainly by two routes, glycolysis and oxidative phosphorylation (OXPHOS). Glycolysis is the 
metabolic pathway that extracts energy from glucose, which is used to reform ATP. OXPHOS is the metabolic path-
way by which cells use enzymes to oxidize nutrients (glucose, fat, protein), thereby releasing energy, which is used to 
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reform ATP. This takes place inside mitochondria. We therefore examined whether or not BBR worked on these two 
routes. We measured the glycolysis marker extracellular acidification rate (ECAR) and the OXPHOS marker oxy-
gen consumption rate (OCR). BBR-treated colitis LP CD4+ T cells showed suppressed OCR and ATP productions 
(Fig. 4B–D). In contrast, BBR-treated colitis LP CD4+ T cells showed elevated ECAR (Fig. 4E). This was due to the 
effect of increased AMPK activation compensating for the loss of ATP production in OXPHOS. However, according 
to the total ATP production in our experiment, glycolysis did not sufficiently compensate for ATP production.
These experiments suggest that BBR suppressed OXPHOS and total ATP production, resulting in AMPK 
activation.
Figure 1. BBR suppressed inflammatory cytokines of LP CD4+ T cells from colitis SCID mice in vitro. (A) 
The cytotoxicity analysis of BBR. Colitis LP CD4+ T cells were stimulated with PMA plus ionomycin mixed 
with BBR (BBR) or not (Control). The bar graphs show number of LP CD4+ T cells. (B) Colitis LP CD4+ T 
cells were stimulated with PMA plus ionomycin mixed with BBR (BBR) or not (Control) for 8 h. After that, 
cells were collected, and intracellular staining was performed to analyze the CD3+CD4+IFN-γ+- or IL-17A+-
producing cells by flow cytometry. Representative flow cytometry images are shown. Flow cytometry showed 
the percentage of CD3+CD4+IFN-γ+-or IL-17A+-producing cells in colitis LP CD4+ T cells. (C) The bar graphs 
show the percentage of IFN-γ- and IL-17A-producing cells in LP CD4+ T cells. All data are reported as the 
mean ± SEM. N is 6 in each group. N.S. not significant. *P < 0.05, **P < 0.01.
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BBR ameliorated experimental colitis in vivo with changes in gut microbiota and decreased 
the production of ifn-γ and IL-17A. Next, we assessed the BBR effects on SCID colitis mouse model 
which injected with CD4+CD45RBhigh T cells. We gave colitis mice a diet mixed with BBR or not and evaluated 
Figure 2. BBR suppressed the Th1/Th17-related JAK/STAT pathway of LP CD4+ T cells collected from colitis 
SCID mice. (A–D) Colitis LP CD4+ T cells stimulated with PMA plus ionomycin were collected and analyzed 
for the JAK/STAT pathway by Western blotting.The left figures show the representative Western blotting images 
of each protein. The cropped blots are used in the figure, and full-length blots are presented in Supplementary 
Fig. S2. All gels were run in the same experimental conditions (see material and methods for details). The bar 
graphs show the percentage of each protein expression. All data are reported as the mean ± SEM. N is 5 in each 
group. *P < 0.05.
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Figure 3. BBR increased AMPK activity and regulated the IFN-γ and IL-17A secretion from colitis LP CD4+ 
T cells. (A) The phosphorylation of AMPK at Thr172 levels in colitis LP CD4+ T cells stimulated with PMA 
plus ionomycin mixed with BBR (BBR) or not (Control) was detected by Western blotting. The left figure is a 
representative blotting image. The right figure is the percentage of pAMPK/AMPK expression. (B-E) Colitis LP 
CD4+ T cells were treated with DMSO, AICAR (250 μM), AICAR (250 µm) mixed with C.C. (400 nM) or C.C. alone 
(400 nΜ) for 30 minutes and stimulated with PMA plus ionomycin for 4 h. After stimulation, cells were collected, 
and intracellular staining was performed to analyze the CD3+CD4+IFN-γ+- or CD3+CD4+IL17A+-producing 
cells by flow cytometry. The cells were then analyzed for AMPK at Thr172 levels by Western blotting. (B) The figure 
shows the representative flow cytometry. (C) The bar graphs show the percentage of cytokine-producing cells. 
(D) The figure shows the representative Western blotting images of AMPK at Thr172 levels. (E) The bar graphs 
show the percentage of pAMPK/AMPK expression. The cropped blots are used in the figure, and full-length blots 
are presented in Supplementary Fig. S3. All gels were run in the same experimental conditions (see material and 
methods for details). All data are reported as the mean ± SEM. N is 5 in each group. *P < 0.05, **P < 0.01.
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the severity of colitis. BBR at a concentration of 0.12% was not effective (Supplementary Fig. S4), but that at 0.35% 
was effective. The clinical and histological scores of the BBR diet group were lower than those of the non-BBR 
diet group (Fig. 5A–D).
To further confirm the effect of BBR on experimental colitis, changes in the immune reactions were examined. 
The numbers of CD4+ T cells in LP were reduced by BBR administration (Fig. 5E). The numbers of IFN-γ- or 
IL-17A-producing LP CD4+ T cells were lower in the BBR diet group than in the non-BBR diet group (Fig. 5F). 
We evaluated the AMPK expression of LP CD4+ T cells in both groups; the expression in the BBR-treated group 
was significantly higher than in the non-BBR-treated group (Fig. 5G).
Given that BBR has been shown to regulate Treg cells by modifying the microbiota in a chemically induced 
IBD model and to regulate Bcl-2 in an in vitro autoimmune disease model29,30, we next examined the change in 
the frequency of Foxp3+ Treg cells and the Bcl-2 expression. The frequency of Foxp3+Treg of LP CD4+ T cells 
were higher and Bcl-2+ of LP CD4+ T cells were lower in the BBR diet group than in the non-BBR diet group 
(Fig. 5H,I).
These data indicated that BBR reduced the T cell inflammatory responses and ameliorated experimental 
colitis.
Figure 4. BBR affected the oxidative phosphorylation and decreased the total adenosine triphosphate 
production. Colitis LP CD4+ T cells were stimulated with PMA plus ionomycin mixed with BBR (BBR) or 
not (Control) for 8 h. (A) After culture, the cells were collected, and the intracellular ATP was analyzed. (B) 
Bioenergetic profile of colitis LP CD4+ T cells. The OCR profile following the addition of mitochondrial 
inhibitors (oligomycin, FCCP, rotenone/antimycin A) was determined by a Flux analyzer xXF 96 S. (C–E) 
The effects of BBR on the OCR, mitochondrial ATP and ECAR profiles were separately analyzed. All data are 
reported as the mean ± SEM. N is 5 in each group. *P < 0.05, **P < 0.01.
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Figure 5. BBR ameliorated experimental colitis in vivo with changes in gut microbiota and decreased the 
production of IFN-γ and IL-17A. A total of 3 × 105 CD4+CD45RBhigh T cells of Balb/c mice were transferred 
into new SCID mice to establish a colitis model (n = 6 per group). After that, a diet including BBR (BBR) or 
not (Control) was given to each group. The mice were monitored for up to seven weeks and then sacrificed 
and analyzed. (A) The gross appearance of the colon, spleen and mesenteric lymph nodes. (B) Clinical scores. 
(C) Histopathology of the distal colon. Original magnification: ×40. (D) Histological scores. Pictures show 
representative samples from each group. (E) Number of LP CD4+CD3+ T cells. (F) Intracellular staining of 
IFN-γ- and IL-17A-producing cells in LP CD4+ T cells. Flow cytometry and a bar graph showing the percentage 
of CD3+CD4+IFN-γ+- or IL-17A+-producing cells in colitis LP CD4+ T cells. (G) The AMPK expression of 
LP CD4+ T cells in both groups. The bar graph shows the percentage of pAMPK/AMPK expression. (H) The 
expression of CD25+Foxp3+ Treg on CD3+CD4+ T cells in the LP. (I) The expression of Bcl2+ on CD3+CD4+ 
T cells in the LP. Cropped blots are used in the figure; full-length blots are presented in Supplementary Fig. S5. 
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Gut microbiota disorder is a known pathogenesis of IBD1. Therefore, we also examined the gut microbiota 
using fecal samples of colitis mice at the time of sacrifice. In both groups, the gut community was mainly built 
by four major phyla, and significant differences were noted in the rates of the Bacteroides and Firmicutes phyla 
(Fig. 6A). Regarding lower classifications, genus-level comparisons showed statistically significant dissimilarities 
in Lactobacillus, Bacteroides, unidentified genus of S24-7 family and Sutterella found in the top 10 most abundant 
genera of both groups (Fig. 6B).
The alpha diversity was evaluated to assess the species richness within the gut microbiota community 
diversity of the two groups (Fig. 6C). There were no considerable differences in the number of observed OTU, 
Faith’s phylogenetic diversity whole tree and the diversity of the species estimated by Chao1. However, interest-
ingly, the species richness and evenness calculated by the Shannon index were significantly reduced with BBR 
supplementation.
The gut microbiota community was measured not only based on the diversity within each group but also 
between the two groups to provide an overview of the gut microbiota structure. An unweighted and weighted 
UniFrac Principle Coordinate Analysis (PCoA) and the UniFrac distance of gut microbiota community in both 
groups were analyzed (Fig. 6D). Both scatter plots demonstrated that gut microbiota structure was changed in 
response to BBR administration. The gray dots representing the BBR diet group gathered closely, while the black 
dots representing the non-BBR diet group seemed scattered. The largest principle coordinates (PC1) were quite 
high, accounting for 35.86% and 79.73% of the total variation in the unweighted and weighted analyses, respec-
tively. In addition, 20.27% and 8.99% of the total variation were the values of second principle coordinate (PC2), 
corresponding to the unweighted and weighted analyses. The shifting of the gut composition under BBR intake 
was indicated in bar plots of the unweighted and weighted UniFrac distance analyses (Fig. 6E). These data sug-
gested that BBR affected the gut microbiota composition, and this change might be one of the factors ameliorating 
colitis.
Discussion
In this report, we showed that BBR ameliorated CD4+ T cell-related chronic colitis in a mouse model and 
revealed the relationship between BBR and AMPK, including its metabolic pathway, through in vitro and in vivo 
experiments.
Our message based on the present data can be summarized in the following three points: 1) We adapted 
the CD4+ T cell-transfer model, a chronic colitis model that clearly differs from the widely used chemically 
induced acute colitis models; 2) BBR affected the AMPK-related metabolic pathway and reduced the inflamma-
tory responses; and 3) BBR reduced the microbiota diversity, possibly by its antimicrobial action.
We used CD4+T cell-transfer colitis models in our in vitro and in vivo experiments, although most previous 
reports used colitis models in which colitis was induced by chemicals, such as DSS17–20. Such chemically induced 
models showed acute colitis that did not accurately reflect the chronic inflammatory process observed in IBD 
patients. CD4+T cell-transfer colitis models show chronic colitis with T cell infiltration, dependent on the micro-
biota, and may be superior to chemically induced models. The use of CD4+T cell-transfer colitis models revealed 
a new inhibitory mechanism of BBR, particularly in relation to colitis LP CD4+ T cells.
The beneficial effects of BBR have been considered to occur due to the activation of AMPK, an energy met-
abolic sensor crucial for cellular energy homeostasis9,10. Recently, many reports have revealed that the immune 
metabolism is a key factor for controlling the immune cell function11–16,31,32. We therefore focused on AMPK 
and attempted to reveal its immunological effects, particularly in relation to colitis LP CD4+ T cells, data on 
which are scarce. Our results showed that BBR increased the AMPK activity in colitic LP CD4+ T cells. In addi-
tion, we showed that the AMPK activity regulated IFN-γ- and IL-17A-producing LP CD4+ T cells. These data 
suggested that the regulation of AMPK in colitis LPCD4+ T cells was important to control mucosal inflamma-
tion. We further investigated the relationship between AMPK and metabolic pathways. It is well-established that 
AMPK is activated under conditions of ATP shortage in order to restore the decreased intracellular energy and 
thereby ensure the cell survival and maintenance of the cell function. After AMPK activation, ATP-consuming 
anabolic pathways are turned off, and ATP-producing catabolic processes are stimulated. Our results showed BBR 
decreased the total ATP content, suggesting that the increase in the AMPK activity was induced by BBR through 
a reduction in the ATP content.
BBR has been shown to inhibit OXPHOS, an oxygen-dependent ATP-producing pathway. OXPHOS is a 
highly efficient way of generating ATP, and almost all aerobic organisms carry out OXPHOS. BBR has been shown 
to inhibit OXPHOS33,34. We therefore further investigated the effects of BBR on the ATP production of colitis 
LPCD4+ T cells. In our study, as expected, BBR inhibited the OXPHOS of colitis LPCD4+ T cells. In our consec-
utive AMPK metabolic pathway experiments, we hypothesized that one of the anti-inflammatory mechanisms of 
BBR was the inhibition of OXPHOS, followed by ATP reduction, AMPK activation, and finally the reduction of 
inflammatory cytokines. Another study showed that AMPK activity was not involved in the reduction of inflam-
matory cytokines, such as IFN-γ and TNF-α, using WT-spleen CD4+ and CD8+ T cells in AMPK conditional 
knockout mice15; however, a precise analysis of the T cells infiltration in the immune mechanism-related IBD 
colon has not been performed. Thus, our data showing the mechanism of AMPK-related mucosal inflammation 
inhibition are novel findings and may highlight a new therapeutic target. The scavenging radical effect of BBR is 
All gels were run in the same experimental conditions (see Materials and methods for details). The numerical 
values represent the mean values of 6 samples per group. Pictures and dot plots of flow cytometry show 
representative samples from each group. All data are shown as the mean ± SEM for 6 mice per group. *P < 0.05, 
**P < 0.01.
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likely to be a key mechanism underlying the anti-colitis effect, as the reduction of OCR and ATP was evident35,36. 
However, our present results indicated the strong effect of BBR on AMPK activation, and an AMPK agonist 
such as BBR may be expected to reduce inflammatory cell activation. We therefore emphasize the importance of 
AMPK in our immune-mediated colitis model as well as the effects of BBR on AMPK activation.
Our results also showed that BBR accelerated glycolysis. It is possible that this activation of glycolysis 
occurred as compensation for the loss of ATP by inhibiting OXPHOS. However, as we did not investigate the 
Figure 6. (A,B) A comparison of the fecal microbial community at the phylum and genus level between colitis 
and BBR. (C) Alpha diversity_Observed OTU, PD whole tree, Chao1 and Shannon index. (D,E) Beta diversity_
UniFrac_unweighted and UniFrac unweighted distance. Each point represents the gut microbiota community 
of each mouse, with black points and gray points indicating the colitis and BBR groups, respectively. All data are 
shown as the mean ± SEM for 6 mice per group. *P < 0.05, **P < 0.01.
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role of glycolysis in relation to LPCD4+T cells, the mechanism was not clearly defined. Previous reports have 
shown that inflammatory cells (e.g. effector memory T cells [TEM cells]) tend to perform glycolysis. In contrast, 
anti-inflammatory cells, such as Foxp3+ regulatory T cells, more often perform OXPHOS37. Further studies are 
needed to gain more insight into the glycolysis of colitis LPCD4+T cells.
In our in vivo experiments, BBR increased the AMPK activity and suppressed inflammatory cytokines in 
colitic LP CD4+ T cells, suggesting that the same mechanism for suppressing inflammation as in in vitro exper-
iments was involved. Concerning inflammatory cytokine control mechanisms by BBR, previous reports have 
shown that Bcl-2 and Foxp3+ Treg cells of LP CD4+ T cells were involved in regulating inflammation38,39. As 
previously reported, BBR reduced the expression of Bcl-2, suggesting the induction of apoptosis of inflammatory 
cells30. Given that our present model contained no natural Tregs, we could investigate only the induced Tregs40. 
The induced Tregs in our present model were increased by BBR administration, in line with the findings of a 
previous report29 (Fig. 5H,I). We also did not examine the detailed relationships between the effects of BBR and 
the characteristics of these cells, including AMPK activity, but the effects of BBR on these cells might offer further 
insight into the regulation of mucosal inflammation.
Our data obtained from in vivo experiments showed that BBR affected the gut microbiota. The gut microbi-
ota have been postulated to induce IBD, including CD and UC41. The modulatory action of BBR was shown by 
changing the bacterial taxonomic structure and reducing the bacterial diversity. Bacteroidetes, a Gram-negative 
phylum, were significantly dominant under BBR supplementation, while the rate of Firmicutes, a Gram-positive 
phylum, was extremely low. A higher response to BBR of Gram-positive bacteria than of Gram-negative bacteria 
was reported in previous studies42. This phenomenon may be due to the permeability barrier of Gram-negative 
bacteria, which can eject both synthetic and natural toxins, including BBR alkaloids, through the activities of their 
multidrug resistance pumps. The penetration of this compound may also be limited due to the outer membranes 
of these bacteria43,44.
BBR had no effect on regulating the richness of gut microbiota in colitis mice, but this reagent seemed to cause 
a remarkable reduction in the gut microbiota diversity. The wide antimicrobial spectrum of BBR has been shown 
to decrease the diversity of intestinal flora45,46. Our data revealed that BBR reduced the severity of colitis and that 
the change in the gut microbiota was due to the anti-inflammatory effects of BBR. We therefore considered the 
change in the gut microbiota in our experiment to be reasonable.
In summary, we showed for the first time that BBR ameliorated CD4+ T cell-related chronic colitis in a mouse 
model with changes in gut microbiota via AMPK activity, possibly induced by the inhibition of OXPHOS, accord-
ing to in vitro and in vivo experiments. The AMPK activity of colonic inflammation may represent a new ther-
apeutic target for IBD, and medicines targeting the AMPK activity, such as BBR, may be recognized as new 
candidates for use in IBD therapy.
Materials and Methods
Animals. Balb/c and CB17-icr SCID mice were purchased from Japan CLEA (Tokyo, Japan). Mice were main-
tained under specific-pathogen-free conditions in the Animal Care Facility of Okayama University. The Balb/c 
donors and recipients were used at 5 to 7 weeks of age. For in vivo experiments of the BBR effect, donors and 
CB17-icr SCID recipients were used at 5 weeks of age.
All protocols and procedures conformed to the guidelines of the Okayama University Committee for Care 
and Use of Laboratory Animals and were approved by the Animal Experiments Ethics Committee of Okayama 
University.
Chemicals. BBR (chloride form) was obtained from Sigma-Aldrich (St. Louis, MO, USA). The resulting com-
pound used in this study had a purity of 98%. For in vitro experiments, BBR was added at a concentration of 
100 µM. For in vivo experiments, we mixed normal diet with BBR at a concentration of 0.35%.
Flow cytometry and antibodies of flow cytometry. To detect the expression of a variety of molecules 
on LP mononuclear cells, they were incubated with antibodies for 20 min. To detect the intracellular expres-
sion, after their surface molecules were stained, cells were fixed using a Cytofix/Cytoperm Kit (BD Pharmingen) 
and incubated with antibodies for 20 min. Multi-color flow cytometric analyses were performed using MACS 
(Miltenyi Biotec, Auburn, CA, USA), a Quant flow cytometer and Flowjo (FlowJo LLC, Ashland, OR, USA).
The following monoclonal antibodies (mAbs) were obtained from Biolegend (San Diego, CA, USA): APC 
anti-mouse CD4 (RM4-5), PE/Cy7 anti-mouse CD3 (145-2C11), PE anti-mouse CD25 (PC61), PE anti-mouse, 
IL-17A (TC11-18H10), FITC anti-mouse IFN-γ (XMG1.2) and Purified anti-mouse CD16/32 (93). The follow-
ing mAbs were obtained from BD Pharmigen (San Diego, CA, USA): FITC anti-mouse CD45RB (16 A); PE 
anti-mouse Bcl-2 (3F11). The following mAbs were obtained from eBioscience (San Diego, CA, USA): FITC 
anti-mouse Foxp3 (FJK-16S).
Induction of CD4+CD45RBhigh T cell-transfer mouse colitis. CD4+ T cells were positivity isolated 
from the spleens of Balb/c mice using anti-CD4 (L3T4) (Miltenyi Biotec) according to the manufacturers’ 
instructions. Enriched CD4+ T cells were labeled with APC anti-mouse CD4 and FITC anti-mouse CD45RB. The 
CD4+CD45RBhigh T cells were isolated using a FACS Aria I (Becton Dickinson). These cells were 98.0%–100% 
pure on a reanalysis. The isolated CD4+CD45RBhigh T cells were intraperitoneally injected into the recipient 
CB17-icr SCID mice with 3 × 105 cells per animal. After transfer, the recipient mice were monitored for clinical 
signs, including a hunched posture, piloerection, diarrhea, and blood in the stool. At autopsy, their clinical scores 
were assessed as the sum of three parameters2: hunching and wasting, 0 or 1; colon thickening, 0–3 (0, none; 1, 
mild; 2, moderate; or 3, extensive); and stool consistency, 0–3 (0, normal beaded stool; 1, soft stool; 2, diarrhea; 
3, bloody stool).
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A histological examination Tissue samples were fixed in phosphate-buffered saline containing 6% 
neutral-buffered formalin. Paraffin-embedded sections (5 μm) were stained with hematoxylin and eosin. Three 
tissue samples from the proximal and distal parts of the colon were prepared. The sections were analyzed without 
prior knowledge of the type of T cell reconstitution or treatment. The mean degree of inflammation in the colon 
was calculated using a modification of a previously described scoring system2, consisting of the sum of three 
parameters: crypt elongation, 0–3; mononuclear cell infiltration, 0–3; and frequency of crypt abscesses, 0–3.
Isolation of mononuclear cells from murine organs. Single-cell suspensions were prepared from the 
LP as described2. To isolate LP CD4+ T cells, the entire length of the colon was opened longitudinally and cut 
into small pieces. The dissected mucosae were incubated for 45 min with Ca2+-, Mg2+- free Hanks’ balanced 
salt solution containing 1 mM dithiothreitol (Sigma-Aldrich) to remove mucus and then treated with 3.0 mg/ml 
collagenase (Roche Diagnostics GmbH, Berlin Germany) for 2 h. The cells were pelleted twice through a Ca2+-, 
Mg2+- free Hanks’ balanced salt solution and then subjected to Ficoll-Paque density gradient centrifugation. 
Enriched LP CD4+ T cells were obtained by positive selection using anti-CD4 (L3T4) MACS magnetic beads. Of 
the resultant cells, > 95% were CD4+ T cells, as determined by flow cytometry.
Cell culture and treatments and intracellular staining of cytokines. LP CD4+ T cells from colitis 
SCID mice were cultured overnight with ionomycin (500 ng/ml), PMA (50 ng/ml) and BD GolgiStop (0.65 l/ml 
BD Pharmingen) mixed with 100 µM of sterile BBR2. After that, cells were collected, and their surface molecules 
were stained. Following cell fixation using a Cytofix/Cytoperm Kit (BD Pharmingen), the cells were incubated 
with PE anti-mouse IL-17A, FITC anti-mouse IFN-γ for 20 min. In some experiments, the designated concen-
trations (in text and figures) of Compound C (C.C.) and 5-Aminoimidazole-4-carboxamide ribonucleotide 
(AICAR) (Selleck Chemicals, Houston, TX, USA) were used to investigate the cellular functions of AMPK15. 
Each experiment contained a group with equal concentrations of DMSO as a control.
Metabolic measurements. LP CD4+ T cells enriched from colitis SCID mice were cultured by the method 
mentioned previously. The extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) were 
measured using with an xXF96 Extracellular Flux Analyzer under mitochondrial stress test conditions (Seahorse). 
Assay buffer was made from non-buffered RPMI 1640 medium supplemented with 2.5 mM dextrose, 2 mM glu-
tamine and 1 mM sodium pyruvate (all from Sigma). The baseline ECAR and OCR values were averaged among 
at least two technical replicates per sample for the first three successive time intervals47.
Measuring the intracellular ATP concentrations. LP CD4+ T cells enriched from colitis SCID mice 
were cultured by the method described previously. After that, cells were collected and plated at 5 × 105 cells in 
96-well plates. The cells were lysed with 100 µl lysis buffer and placed directly into the chamber of a luminom-
eter (Flex Station3, Molecular Devices, CA, USA). Light emission was recorded after the addition of 100 µl of 
luciferin-luciferase solution (TOYO B-NET, Tokyo, Japan). The ATP values were averaged among at least two 
technical replicates per sample.
Western blotting analyses. Total proteins were extracted from cultured LP CD4+ T cells using a protein 
extraction kit (Minute Protein Extraction Kit; Invent Biotechnologies, Inc., Eden Prairie, MN, USA). Extracted 
proteins were quantitated by the BCA method (BCA protein Assay Kit; Takara Bio, Inc., Otsu, Japan) and diluted 
to the same protein concentrations. Equivalent amounts of each group were run on SDS polyacrylamide gels. 
Proteins were transferred electrically to a PVDF membrane (Bio-Rad, Hercules, CA, USA). The membranes were 
blocked using polyvinylidene fluoride Blocking Reagent (Toyobo, Osaka, Japan) for 1 h. After that, the mem-
branes were incubated with the following rabbit monoclonal antibodies overnight at 4 °C: anti-AMPK(Thr172), 
anti-stat1(Tyr701), anti-stat3(Tyr705), anti-JAK1(Tyr 1034/1035), anti-JAK2 (Tyr221) (Cell Signaling 
Technology, Inc., Beverly, MA, USA). After three washes with Tris-buffered saline with Tween-20 (Sigma), the 
membranes were incubated with secondary antibodies for 1 h at room temperature. The rabbit monoclonal anti-
bodies were used at a 1:1000 dilution and the anti-rabbit secondary antibodies (Cell Signaling Technology) at a 
1:2000 dilution. Bands were detected by using a LAS 4000 imager (GE Healthcare Life Sciences, Pittsburgh, PA, 
USA). β-actin was used as a loading control. Contrast was adjusted with Adobe Photoshop Elements 14. The 
quantity in each sample was analyzed using an Image J64 (NIH, Bethesda, MD, USA).
Gut microbiome analyses of mice. Fresh fecal samples of mice were collected, immediately frozen by 
liquid nitrogen, and stored at −80 °C until use. The DNA purification of fecal samples was conducted according to 
the previous methods with slight modification48. The fecal DNA was sequenced using Illumina Miseq platforms 
according to the manufacturer’s recommendation (San Diego, CA, USA).
The raw sequences of both the BBR diet group and non-BBR diet group were processed using the QIIME 
software package, version 1.9.1 (http://qiime.org/) _ENREF_4149. After quality filtering, all sequences were nor-
malized to the smallest number of reads (5324 reads) before being assigned operation taxonomic units (OTUs) 
using the Greengenes reference database with a 97% similarity threshold, and the alpha and beta diversity were 
compared. The relative abundance of OTUs in each group was evaluated at the phylum and genus levels. Chao1, 
observed species, Faith’s phylogenetic diversity whole tree and the Shannon diversity index were determined to 
estimate the alpha diversity. The weighted and unweighted UniFrac distance in beta diversity were evaluated to 
compare the microbial diversity between the BBR diet group and non-BBR diet group. All DNA sequences are 
available on the Sequence Read Archive under the relevant project identification number.
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Statistical analyses. Results are expressed as means ± standard error of the means for parametric 
data and medians for non-parametric data. All parametric data were compared using the Student’s t test, and 
non-parametric data were compared by the Mann Whitney U-test. Data were considered to be statistically signif-
icant at P < 0.05. The Statcel software program, version 3 (OMS Publishing Company, Saitama, Japan) was used 
for all statistical analyses.
Data Availability
Contact the authors or provide an SRA number.
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